Kidney Disease Biomarkers

NCT00255398 | Completed

• 2 other identifiers: 06002006-DK-0020
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Kidney Disease Biomarkers Summary: This study will identify biomarkers (proteins and other molecules in the blood or urine) that may help scientists predict what kidney disease a patient has and whether a given patient would respond to particular therapies. The study will look for biomarkers in the blood and urine of patients with various kidney diseases and study of the effects of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARB) on biomarkers. Blood and urine from healthy volunteers will be studied for comparison. Healthy people and the following patients may be eligible for this study: adults with diabetic nephropathy 18 years of age and older; children with newly diagnosed clinical idiopathic nephrotic syndrome between 2 and 18 year of age; children and adults with glomerular disease (minimal change disease, focal segmental glomerulosclerosis, or collapsing glomerulopathy). Participants undergo tests and procedures as follows: Glomerular Disease: Adults with glomerular disease provide about four to six blood and urine samples over the course of 6 to 12 months. The samples are collected at the time of regularly scheduled visits for the NIH treatment protocol in which they are participating. Children provide only blood samples. Chronic Kidney Disease: Patients with chronic kidney disease provide a blood and urine sample every 6 months for 3 years or more. Angiotensin Antagonism: Patients with chronic kidney disease who are taking ACE inhibitors or ARBs stop their medicines for 4 weeks, while those who are not taking ACE inhibitors or ARBs begin one of the medicines. In general, patients just starting on the medications continue them after the study is completed, since they are beneficial for chronic kidney disease.

• Medication withdrawal group: Patients come to NIH for 2 successive days at the beginning of the study for blood and urine tests (including one 24-hour urine collection) and to receive iothalamate (a chemical used to measure kidney function). Iothalamate is delivered over 24 hours through a needle placed in the abdomen (or elsewhere) via a pump similar to pumps that some diabetics use to deliver insulin. Patients then stop taking their ACE inhibitor or ARB medication. They monitor their blood pressure every day and return to NIH after 1, 2 and 4 weeks for blood tests. During week 4, the iothalamate infusion is repeated, and blood and urine samples are collected as at the beginning of the study. Patients then resume taking their ACE inhibitor or ARB once a day with the dose being increased at 2-week intervals. They come to NIH weekly after 1 week and then every other week for blood tests. Four weeks after reaching the highest FDA-recommended dose of medication tolerated, the iothalamate infusion and blood and urine collections are repeated.
• Medication induction group: At the beginning of the study, patients have the iothalamate infusion and blood and urine collections described above and then begin to take either an ACE inhibitor or ARB. The dose is increased after 2 weeks. Patients monitor their blood pressure every day. After being on the highest dose for 4 weeks, patients repeat the iothalamate infusion and blood and urine collections. The study is then complete and they are provided a 2-month supply of medicine to take home. Information is gathered on symptoms, treatments, and results of past laboratory tests of all patients. Healthy volunteers provide blood and urine sample collections every month or every other month for up to four collections to be used for biomarker studies and the screen for common chronic diseases.

Conditions

Kidney Disease; Glomerular Disease; Idiopathic Nephrotic Syndrome; Focal Segmental Glomerulosclerosis; Collapsing Glomerulopathy

Keywords

Focal Segmental Glomerulosclerosis; Minimal Change Disease; Diabetic Nephropathy; Mass Spectrometry; Proteinuria; Idiopathic Nephrotic Syndrome; Glomerular Disease; FSG; Kidney Disease

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Children with newly diagnosed clinical idiopathic nephrotic syndrome between the ages of 2-18 years.
• Children with previously diagnosed clinical idiopathic nephrotic syndrome between the age of 2-18 years at the time of diagnosis who sustain a relapse of nephrotic syndrome while off steroid therapy. A relapse is defined as a urine protein level of 2+ (100mg/dl) or greater on a first morning urine sample for 3 consecutive days. While a quantitative urine protein/creatinine ratio is more precise, this semi-quantitative definition accords with pediatric practice. Relapses will be treated according to standard clinical practice.
• Children and adults who participate in NIH trials of remittive therapy for MCD/FSGS/CG (e.g. Podocyte dexamethasone or Retinoids for podocyte disease) will be eligible.
• Also, we will study up to 10 healthy adult volunteers.

You may not qualify if:

• IN CHILDREN, ANY OF THE FOLLOWING
• Age less than 2 years. The rationale for excluding children under the age of 2 yr is that nephrotic syndrome is unusual in this age group and may have etiologies other than MCD and FSGS
• Uncontrolled hypertension (a systolic or diastolic which is greater than 95% population mean for child s age and sex, while receiving therapy), azotemia (serum creatinine greater than 1.5mg/dL), gross hematuria at the time of presentation (clinical markers of primary or secondary GN).
• Hypocomplementemia, positive ANA, anti-DS DNA, ASO, anti-DNase B, MPO, PR-3, Hepatitis B and C and HIV serologies.
• In children or adults:
• Clinical contra-indications to steroid therapy.
• The presence of medical conditions that might interfere with the interpretation of results, such as cancer, diabetes, or a long history of hypertension.
• Healthy adult volunteers:
• age greater than 18 yrs; no history of hypertension, diabetes, or other chronic illness that might complicate interpretation of the results; not taking prescription medication.
• CKD PROGRESSION STUDY:
• Renal biopsy diagnosis of glomerular disease or interstitial nephritis or clinical diagnosis of diabetic nephropathy.
• Mild or moderate renal insufficiency, defined as eGFR less than 60 ml/min/1.73m(2) but greater than 30 ml/min/1.73m(2).
• \) The presence of medical conditions that might interfere with the interpretation of results, such as cancer.
• ANGIOTENSIN ANTAGONISM STUDY:
• Adults greater than 18 years old. Few children have diabetic nephropathy and the frequent blood draws would be problematic for children.

Sponsors & Collaborators

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Barisoni L, Kopp JB. Modulation of podocyte phenotype in collapsing glomerulopathies. Microsc Res Tech. 2002 May 15;57(4):254-62. doi: 10.1002/jemt.10084.

  PMID: 12012394 BACKGROUND

• Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol. 2003 Mar;23(2):147-60. doi: 10.1053/snep.2003.50024.

  PMID: 12704575 BACKGROUND

• Hortin GL, Meilinger B, Drake SK. Size-selective extraction of peptides from urine for mass spectrometric analysis. Clin Chem. 2004 Jun;50(6):1092-5. doi: 10.1373/clinchem.2003.030742. No abstract available.

  PMID: 15161733 BACKGROUND

MeSH Terms

Conditions

Kidney Diseases; Nephrosis, Lipoid; Glomerulosclerosis, Focal Segmental; Diabetic Nephropathies; Proteinuria

Condition Hierarchy (Ancestors)

Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Nephrosis; Glomerulonephritis; Nephritis; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Urination Disorders; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Jeffrey B Kopp, M.D.

  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2006
• First Posted: November 18, 2005
• Study Start: November 10, 2005
• Study Completion: December 3, 2014
• Last Updated: December 17, 2019

Record last verified: 2014-12-03

Locations

US (1)